WAVE Life Sciences Ltd. is a WAVE Life Sciences Ltd is a preclinical biopharmaceutical company based in Singapore.
WAVE Life Sciences Ltd. (WVE) had a rough trading day for Wednesday March 10 as shares tumbled 5.95%, or a loss of $-0.59 per share, to close at $9.33. After opening the day at $9.95, shares of WAVE Life Sciences Ltd. traded as high as $10.16 and as low as $8.94. Volume was 1.25 million shares over 9,364 trades, against an average daily volume of n/a shares and a total float of 49 million.
As a result of the decline, WAVE Life Sciences Ltd. now has a market cap of $457.15 million. In the last year, shares of WAVE Life Sciences Ltd. have traded between a range of $19.98 and $6.62, and its 50-day SMA is currently $n/a and 200-day SMA is $n/a.
WAVE Life Sciences Ltd is a preclinical biopharmaceutical company based in Singapore. It owns a diverse pipeline of nucleic acid therapeutics meant to address rare genetic diseases related to the central nervous system, muscles, eyes, liver, and skin. Its nucleic acid therapeutics target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.
WAVE Life Sciences Ltd. is based out of Singapore, and has some 301 employees. Its CEO is Paul B. Bolno.